Organic Active Ingredients TRIZ Cases

Targeted substituent changes on tryptamine analogues preserve receptor docking and binding while expanding compound diversity for medicament use.

Crenolanib targets FLT3-mutated AML with NPM1 or NUP98 drivers to reduce blood and bone marrow blasts and improve survival.

Combining polaprezinc with enzalutamide helps overcome CRPC drug resistance and improves tumor growth inhibition over single-drug therapy.

A new N-(1H-imidazol-2-yl)benzamide scaffold improves IRAK-4 inhibition for autoimmune disease and lymphoma treatment with fewer side effects.

Sequential tTF-NGR vascular occlusion and Trabectedin retention improve soft-tissue sarcoma response while limiting systemic toxicity.

An industrial Acalabrutinib route uses in-situ coupling and mild deprotection to avoid chromatography, cryogenic steps, and microwave reactions.

Dual IRAK1/4 and FLT3 inhibition targets resistant AML and MDS pathways to extend remission and slow progression to leukemia.

A rotatable applicator uses audible and tactile dose indexing to improve dosing accuracy for flowable pharmaceuticals while limiting evaporation and contamination.

Ultrasound-triggered liposomes use cavitation and sonodynamic action to break biofilms, improve antibiotic penetration, and prevent regrowth.

A gel-wrapped enteric granule system improves 24-hour release control and mixing uniformity for low-dose insoluble oral drugs.

Deuterium-enriched neuroactive steroids improve GABAA receptor modulation and brain excitability control for CNS disorder treatment.

Engineered T cells use trehalase and trehalose transport to sustain metabolism and tumor killing in glucose-deprived solid tumors.

Targeting ELOVL6 lowers mutant KRAS levels in KRAS-dependent cancer cells, offering an indirect route for hard-to-drug variants such as G12V.

Surfactants and viscosity enhancers stabilize ophthalmic drugs for room-temperature storage, extending shelf life without cold-chain handling.

2-bromo-LSD-based compositions separate antidepressant and anxiolytic effects from hallucinogenic psychiatric reactions through 5-HT2A blockade.

Prodrug-loaded adhesive patch matrices enable stable skin delivery of acetaminophen or ibuprofen while avoiding gastrointestinal issues.

A powder that hydrates into a crosslinked mucoadhesive hydrogel helps periodontal agents stay longer on oral surfaces and block contamination.

Reduced nalbuphine dosing with 7-30 day titration helps elderly patients maintain efficacy while lowering toxicity risk from age-related pharmacokinetic changes.

Halogenated benzofurans speed CNS therapeutic response while reducing toxicity, abuse liability, and cardiovascular risk.

A single vector coordinates Cas3 and Cascade expression with inducible promoters to cut toxicity and mutation while improving DNA amplification yield.

A biodegradable intravitreal implant uses corticosteroid-fatty acid complexes to sustain ocular drug release and reduce repeat injections.

Blocking FABP4 helps accelerate angiogenesis, reduce inflammation, and improve wound closure with less scarring, including in diabetic wounds.

Gamma secretase inhibition raises cell surface BCMA and lowers soluble BCMA, improving the effectiveness of BCMA-targeting therapy.

Specific excipient combinations improve IRAK4 inhibitor dissolution, lower impurity content, and maintain tablet stability for oral dosing.

Dual HER2 epitope targeting improves response and disease control in HER2-positive biliary tract cancer where current therapy offers limited survival benefit.

Chelating nanoparticles sequester calcium deposits in blood vessels to suppress SASP and senescence without apoptosis-linked hemorrhage.

High-specific-surface-area cannabinoid crystals improve oral uptake and sustained bloodstream delivery without complex SEDDS formulations.

Isolated brucine offers an ALS treatment route that delays onset and supports survival while avoiding the narrow toxic window of Nux vomica seed.

Phosphate budesonide salts improve water solubility and formulation stability, avoiding deposition issues in nebulized respiratory delivery.

SARM1 activators such as 3-APMN and VMN enable localized neurolysis by triggering selective axon degeneration while sparing adjacent tissues.

Modular polynucleotides bind pre-mRNA and recruit spliceosomes to correct splicing and lower Tau and amyloid β expression.

Lipophilic particles with penetration enhancers and surfactants improve hair growth drug retention and skin permeability while reducing irritation.

A short-chain polypeptide paired with guanine nucleotide and succinic acid boosts collagen production synergistically for aging skin care.

A hydrogen-bonded enavogliflozin-proline co-crystal improves solubility while maintaining stability and extending oral drug exposure.

Pre-formed starch hydrogel beads retain doxorubicin and radionuclides at tumor sites for sustained local therapy with minimal systemic exposure.

Iridoid-rich Eucommia male flower extract activates mitophagy to improve mitochondrial function and help resist age-related muscle decline.

Naked RNA oligonucleotides tune megakaryocyte and platelet gene expression to lower thrombosis risk while preserving hemostasis and limiting bleeding.

Spirocyclic dihydropyranopyrimidine compounds bind dysregulated KRAS to inhibit sustained activation in cancers linked to KRAS mutations.

Structure-based small molecules target tau and alpha-synuclein fibrils to disassemble toxic aggregates while improving brain penetration.

Ascomycin is used to restore BMPR2 signaling in pulmonary hypertension, aiming to improve hemodynamics while avoiding limits of current therapies.

Selective heterocyclic compounds block MAGL to raise 2-arachidonoylglycerol levels, helping reduce neuroinflammation and related disorders.

Higher-then-lower drospirenone dosing relieves endometriosis pain and dysmenorrhea while maintaining contraception and supporting amenorrhea.

Hexacyclic topoisomerase inhibitors improve solubility and stability while retaining cytotoxicity, enabling more effective ADC payloads for cancer treatment.

Cleavable ester and disulphide groups help cationic lipids encapsulate nucleic acids efficiently while limiting toxic by-products in vivo.

Targeting MST1/2 or LATS1/2 inhibition reduces pro-inflammatory cytokines and fibrosis in chronic nephropathies such as nephronophthisis.

Steroid pre-dosing before KRAS G12C inhibitor and pembrolizumab helps curb hepatotoxicity and adverse events in NSCLC treatment.

3-position piperidine substitution blocks metabolization and ring opening in BTK inhibitors, preserving binding affinity and efficacy.

A controlled-release selexipag formulation slows absorption, stabilizes plasma levels, and helps prevent alcohol dose dumping.

RNAi suppression of HBV gene expression paired with an anti-HBV antibody lowers HBsAg and viral load while reducing antibody dose and toxicity.

Antisense inhibition of Complement Factor B lowers C3 buildup in eye and kidney tissues while modulating alternative pathway overactivation.